Atrium Therapeutics, Inc. Common Stock Cash Flow Reinvestment Rate
Atrium Therapeutics, Inc. Common Stock cash flow reinvestment rate. Atrium Therapeutics, Inc. Common Stock (RNA) has a Cash Flow Reinvestment Rate of 3.15x as of December 2023, reinvesting $51.90 Million (capex $863.00K plus investments $51.04 Million) from operating cash flow of $16.50 Million. Explore cash flow to debt ratio of Atrium Therapeutics, Inc. Common Stock to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Atrium Therapeutics, Inc. Common Stock (2019–2019)
Cash flow reinvestment rate of Atrium Therapeutics, Inc. Common Stock from 2019 to 2019. Historical reinvestment intensity for Atrium Therapeutics, Inc. Common Stock across 1 annual periods. Explore RNA capital expenditure intensity to see what proportion of operating cash flow is directed to capital expenditures.
Atrium Therapeutics, Inc. Common Stock Cash Flow Reinvestment Rate by Year (2019–2019)
Atrium Therapeutics, Inc. Common Stock cash flow reinvestment rate by year from 2019 to 2019. Year-by-year capital reinvestment analysis for Atrium Therapeutics, Inc. Common Stock. For the full cash flow conversion analysis, see RNA cash flow metrics.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2019 | 0.19x | $470.00K | $2.49 Million | $235.00K | — |